Dicerna Pharmaceuticals Garners $25,000,000 Series B Funding

  • Feed Type
  • Date
    8/11/2010
  • Company Name
    Dicerna Pharmaceuticals
  • Mailing Address
    480 Arsenal Street Building 1 Watertown, MA 02472
  • Company Description
    Dicerna Pharmaceuticals is a venture-backed startup developing novel therapeutics in multiple therapeutic areas based on Dicer substrate technology, which makes use of the RNA interference mechanism.
  • Website
    http://www.dicerna.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $25,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from the financing will be used to advance Dicerna’s lead in-house program in oncology towards clinical development and progress its other preclinical programs. The company also plans to use the proceeds to continue to develop conjugated drug delivery systems, which combine Dicerna’s DsiRNA molecules with targeting moieties such as peptides, aptamers or antibodies, potentially allowing for direct delivery into specific cells of interest.
  • M&A Terms
  • Venture Investor
    Domain Associates
  • Venture Investor
    Oxford Bioscience Partners
  • Venture Investor
    Abingworth Management Inc
  • Venture Investor
    Skyline Ventures

By posting a comment, you agree to our terms and conditions.